Results of the PCaI prostate cancer patient “value” survey

Earlier this year, in late May and early June, Prostate Cancer International (PCaI) conducted what we have described as a very primitive pilot survey on prostate cancer patients’ perceptions of “value” in the management of this disease. … READ MORE …

“Why gene tests for cancer don’t offer more answers”

An article with the above title appears to be scheduled for upcoming publication in Scientific American but is already available on line on the Scientific American web site. It may be of interest to a number of our readers. … READ MORE …

A new set of risk strata to define prognostic risk for men with localized prostate cancer

A newly published paper in the journal PLoS Medicine has set out a new set of definitions of five “risk strata” into which we can subdivide men diagnosed with prostate cancer. … READ MORE …

“Black lives matter” when it comes to prostate cancer too

In an OpEd in today’s New York Times, there is a passionate plea for greater focus on the risks and dangers that prostate cancer presents to African-American men. … READ MORE …

Defining value in the management of prostate cancer

Many years ago, among his other famous quotations on the subject of prostate cancer, Willet Whitmore, considered by many to be the “father” of urologic oncology, stated the following: … READ MORE …

It was true 3 years ago, but is it still the case?

One of the problems with a lot of research is that it is out of date by the time it is published. The following example may be a classic case in point. And it has serious implications. … READ MORE …

PRIAS reports data from a 5,000+ patient active surveillance study

Data from a recent paper in European Urology has further confirmed the value of active surveillance as a first-line management option for men diagnosed with low-risk prostate cancer. It has also confirm recent guidance for when men on active surveillance actually need to be advised that treatment is probably wise. … READ MORE …